We use our own cookies and third parties ones to offer our services and collect statistical data. If you continue browsing the internet you accept them. More information

Accept
What is permanens
What is Permanens?

What is Permanens?

PERMANENS aims to incorporate data-driven risk assessments and evidence-based care components into emergency clinical care for patients with self-harm, hereby preventing adverse outcomes such as suicide and premature mortality, while enhancing the standardization and continuity of care.
Know more
Objectives

Objectives

Research team

Research team

Publications

Publications

Methodology

Methodology

Ethical Aspects

Ethical Aspects

The project

The PERMANENS research project aims to develop a prototype of a Clinical Decision Support System (CDSS) software, designed to assist clinicians in the assessment and care of patients presenting with self-harm in the emergency department. Trained on evidence accumulated in clinical settings and based on the patient’s particular clinical history, the CDSS will provide clinicians with personalized risk profiles for relevant adverse outcomes, including self-harm, method escalation, suicide, premature mortality, as well as discontinuation of care. The CDSS will provide a summary of the most critical risk factors and propose an evidence-based treatment plan, tailored precisely to the patient’s individual risk profile.

Know more
The project
About us

About us

The PERMANENS consortium brings together world-leading expertise in suicide research, clinical mental health, public health, biostatistics, and biomedical informatics. Participating institutions include the Hospital del Mar Research Institute, University of Oslo, Karolinska Institute, University College Cork, and Pompeu Fabra University.

Know more

Blog

Last news
Gobierno de España Instituto de Salud Carlos III European Union ERA Per Med

The PERMANENS project is supported by Instituto de Salud Carlos III (ISCIII) and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (AC22/00006; AC22/00045), the Swedish Innovation Agency (no. 2022-00549), the Research Council of Norway (project no. 342386) and the Health Research Board Ireland (ERAPERMED2022) under the frame of ERA PerMed.